[Humoral immune response to HIV-2 in Mexico] NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Humoral immune response to HIV-2 in Mexico]

Salud Publica Mex. 1995 Sep-Oct;37(5):394-9. Unique Identifier : AIDSLINE MED/96166536
Valadez-Gonzalez N; Soler-Claudin C; Unidad de Investigacion en Retrovirus Humanos, Instituto de; Investigaciones Biomedicas, Universidad Nacional Autonoma de; Mexico.

Abstract: OBJECTIVE. To study the reactions of Mexican HIV-1 positive sera to HIV-2 antigens, and their relation to the mode of transmission and the clinical status of infected individuals. MATERIAL AND METHODS. Six-hundred and fifty-four sera samples collected in Mexico were tested using HIV-2 immunoblot (IB) techniques; 492 samples were from HIV-1 positive cases and 162 from HIV-1 negative controls. RESULTS: Seventy-nine percent (388/492) of the HIV-1 reactive sera showed reactivity with at least one HIV-2 protein: 71% (352/492) recognized the capsid protein p24, 24% (119/492) the transmembrane glycoprotein and 9% (44/492) the external glycoprotein of HIV-2. Considering the transmission mechanism, HIV-2 reactivity occurred in 81% (324/401) of the sexually infected patients, and only in 39% (16/41) of people infected through blood products. Ten highly reactive gp32 HIV-2 sera samples were titrated and results showed that reactivity with HIV-1 gp41 was always higher than that to HIV-2 gp32. HIV-1-HIV-2 dual infection was discarded by negative results with the commercial assay Liatek HIV 1+2. CONCLUSIONS. We propose that the serological cross-reactivity found can be due to a possible initial introduction in Mexico of two different viral strains through the two main transmission routes and that the strains circulating in sexually infected individuals are more similar to the HIV-2 strains, at least with respect to their glycoproteins, than the HIV-1 strains predominant in other countries.
Keywords: Acquired Immunodeficiency Syndrome/TRANSMISSION Blood Transfusion/ADVERSE EFFECTS Comparative Study Cross Reactions English Abstract Female Human HIV Antibodies/ANALYSIS HIV Seronegativity *HIV Seropositivity HIV-1/IMMUNOLOGY HIV-2/*IMMUNOLOGY Male Mexico Support, Non-U.S. Gov't JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/transmissionbloodtransfusion/adverseeffectscomparativestudycrossreactionsenglishabstractfemalehumanhivantibodies/analysishivseronegativityKWDhivseropositivityhiv-1/immunologyhiv-2/KWDimmunologymalemexicosupport,non-uKWDsKWDgov'tjournalarticle
960730
M9670492

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .